Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Target Price at $4.55

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been given an average rating of “Hold” by the fourteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $4.3636.

A number of analysts have commented on the company. Piper Sandler downgraded Health Catalyst from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $8.00 to $4.00 in a research report on Wednesday, August 27th. Evercore ISI cut their target price on Health Catalyst from $4.00 to $3.00 and set an “in-line” rating for the company in a research note on Wednesday, October 8th. BTIG Research reiterated a “neutral” rating on shares of Health Catalyst in a research note on Friday, September 5th. Canaccord Genuity Group lowered their price target on shares of Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, August 29th. Finally, Citigroup dropped their price objective on shares of Health Catalyst from $3.50 to $3.25 and set a “neutral” rating for the company in a research note on Tuesday.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $2.46 on Monday. The company’s fifty day moving average is $3.01 and its two-hundred day moving average is $3.50. Health Catalyst has a 52-week low of $2.44 and a 52-week high of $9.24. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.83. The firm has a market capitalization of $174.00 million, a price-to-earnings ratio of -1.55 and a beta of 1.64.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.01. Health Catalyst had a negative net margin of 34.05% and a negative return on equity of 6.67%. The business had revenue of $76.32 million during the quarter, compared to analyst estimates of $75.05 million. Health Catalyst has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts forecast that Health Catalyst will post -0.33 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Health Catalyst in the 3rd quarter valued at approximately $39,000. Cresset Asset Management LLC acquired a new stake in Health Catalyst in the 2nd quarter valued at $39,000. Divergent Planning LLC acquired a new stake in Health Catalyst in the 2nd quarter valued at $45,000. Focus Partners Wealth bought a new stake in Health Catalyst in the first quarter valued at $46,000. Finally, AXQ Capital LP acquired a new position in Health Catalyst during the third quarter worth $51,000. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.